EQT Acquires Igenomix from Charme Capital; Management and Charme Reinvest

EQT, ADIA and CPP Investments to Acquire QIAGEN

July 9, 2026

Biotechnology

EQT Private Equity, alongside co-investments from the Abu Dhabi Investment Authority through Luxinva and CPP Investments, agreed to acquire QIAGEN in an all-cash public takeover valuing the company at approximately €10.8 billion. The €46.50-per-share offer is subject to shareholder acceptance and regulatory approvals, with completion expected in mid-2027; QIAGEN says private ownership would support long-term investment in innovation, R&D and growth.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

Vitrolife Acquires Igenomix from EQT and Charme for EUR 1.25 billion

July 8, 2021

Healthcare Services

Vitrolife AB has agreed to acquire Igenomix from EQT Private Equity and Charme Capital Partners for an enterprise value of EUR 1.25 billion. The deal combines Vitrolife's IVF product business with Igenomix's reproductive genetic testing capabilities to create a global leader in reproductive health; sellers will retain minority stakes in Vitrolife and the transaction will be funded with cash and newly issued shares.

EQT Private Equity and Goldman Sachs Asset Management Acquire Parexel from Pamplona Capital Management

July 2, 2021

Healthcare Services

EQT Private Equity (EQT IX) and Goldman Sachs Asset Management's Private Equity business have agreed to acquire Parexel from Pamplona Capital Management for an enterprise value of USD 8.5 billion. Parexel, a global clinical research organization co-headquartered in Durham, North Carolina and Newton, Massachusetts, employs more than 17,000 people and provides outsourced clinical development, regulatory, market access and consulting services to the pharma and biotech industry.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Igenomix Acquires Access Genomics Canada from Persistence Capital Partners

December 14, 2020

Biotechnology

Igenomix, a Spanish reproductive-genetics company, acquired Toronto-based laboratory Access Genomics (Access Genomics Canada) from Persistence Capital Partners on December 14, 2020. The acquisition expands Igenomix’s presence in North America and strengthens its ability to serve fertility clinics in the Toronto area.